发明公开
- 专利标题: GLUCAGON ANTAGONISTS
- 专利标题(中): 胰高血糖素ANTAGONISTEN
-
申请号: EP09791510.2申请日: 2009-08-13
-
公开(公告)号: EP2326618A1公开(公告)日: 2011-06-01
- 发明人: GOMEZ-GALENO, Jorge, E. , HECKER, Scott, J. , DANG, Qun , REDDY, Mali Venkat , SUN, Zhili , GROTE, Matthew, P. , NGUYEN, Thanh Huu , LEMUS, Robert, Huerta , LI, Haiqing
- 申请人: Metabasis Therapeutics, Inc.
- 申请人地址: 11119 North Torrey Pines Road La Jolla, CA 92037 US
- 专利权人: Metabasis Therapeutics, Inc.
- 当前专利权人: Metabasis Therapeutics, Inc.
- 当前专利权人地址: 11119 North Torrey Pines Road La Jolla, CA 92037 US
- 代理机构: UEXKÜLL & STOLBERG
- 优先权: US88697P 20080813
- 国际公布: WO2010019830 20100218
- 主分类号: C07C309/15
- IPC分类号: C07C309/15 ; C07D263/57 ; A61K31/167 ; A61K31/423 ; A61P3/10
摘要:
Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co- crystals and prodrugs thereof. Formula I
公开/授权文献
- EP2326618B1 GLUCAGON ANTAGONISTS 公开/授权日:2014-10-15
信息查询